India, July 27 -- Glenmark Life Sciences Limited ('GLS' or the 'Company'), a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients ("APIs") in chronic therapeutic areas, plans to open its Initial Public Offering ("Offer") on July 27, 2021.
The Price Band of the Offer has been fixed at Rs 695 to Rs 720 per Equity Share. Bids can be made for a minimum of 20 Equity Shares and in multiples of 20 Equity Shares thereafter.
The Offer consists of equity shares of face value of Rs 2 each of Glenmark Life Sciences Limited ("Equity Shares") comprising a fresh issue of Equity Shares aggregating to Rs 10,600 million (the "Fresh Issue") and an offer for sale of up to 6,300,000 Equity Shares by Glenm...